These data suggest that increased CD44 or SLC16A1 expression is a probable prognostic marker in pancreatic cancer patients and is related to tumor aggressiveness mediated by metabolic reprogramming, CSC phenotype, and rapid cell proliferation. The gene discussed is CD44; the disease is neoplasm.